TerminatedPhase 3NCT03495921

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Studying Bone sarcoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Gradalis, Inc.
Principal Investigator: John Nemunaitis, MD
Gradalis, Inc.
Intervention: Vigil(biological)
Enrollment: 32 enrolled
Eligibility: 2 years · All sexes
Timeline: 2018 – 2022

Study locations (15)

Arkansas Children's Hospital, Little Rock, Arkansas, United States
Southern California Permanente Medical Group, Los Angeles, California, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
Nicklaus Children's Hospital, Miami, Florida, United States
Dana-Farber/Boston Children's Cancer and Blood Disorders, Boston, Massachusetts, United States
Washington University Siteman Cancer Center, St Louis, Missouri, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Duke Children's Hospital and Health Center; Duke Cancer Institute, Durham, North Carolina, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Texas Oncology - Pediatrics, Dallas, Texas, United States
Cook Children's Medical Center, Fort Worth, Texas, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03495921 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma →

← Back to all trials